Transgender Medicine pp 143-163 | Cite as
Endocrine Care of Transgender Adults
- 1 Citations
- 4 Mentions
- 997 Downloads
Abstract
Since the mid-twentieth century, transgender individuals have become increasingly visible. Strong advocacy group efforts and increasing government support have improved access to medical care for people with gender dysphoria. Physicians should be aware of the unique conditions and challenges affecting this population. Healthcare professional organizations such as the American Medical Association (AMA), the Endocrine Society, and the World Professional Association for Transgender Health have concluded that hormonal and surgical treatment of gender dysphoria is medically necessary to prevent long-term morbidity. Furthermore, physicians caring for transgender persons must have sufficient experience to recognize gender dysphoria as a spectrum of conditions, and should be adept in tailoring therapy to the individual patient. Many, but not all, gender dysphoric individuals presenting for care will ultimately seek endocrine therapy for the modulation of endogenous hormone production and exogenous hormone supplementation, to improve their quality of life.
Keywords
Testosterone Transgender Treatment Sex Therapy Gender Hormone EstrogenReferences
- 1.Leinung MC, et al. Endocrine treatment of transsexual persons: extensive personal experience. Endocr Pract. 2013;19(4):644–50.PubMedGoogle Scholar
- 2.Hembree WC, et al. Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(9):3132–54.PubMedGoogle Scholar
- 3.Spack NP, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics. 2012;129(3):418–25.PubMedGoogle Scholar
- 4.de Vries AL, Cohen-Kettenis PT. Clinical management of gender dysphoria in children and adolescents: the Dutch approach. J Homosex. 2012;59(3):301–20.PubMedGoogle Scholar
- 5.Steensma TD, et al. Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study. Clin Child Psychol Psychiatry. 2011;16(4):499–516.Google Scholar
- 6.Smith KP, Madison CM, Milne NM. Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults. Pharmacotherapy. 2014;34(12):1282–97.PubMedGoogle Scholar
- 7.Schagen SE, et al. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016;13(7):1125–32.PubMedGoogle Scholar
- 8.Carswell JM, Roberts SA. Induction and maintenance of amenorrhea in transmasculine and nonbinary adolescents. Transgender Health. 2017;2(1):195–201.PubMedPubMedCentralGoogle Scholar
- 9.Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903.PubMedGoogle Scholar
- 10.Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017;5(4):291–300.PubMedGoogle Scholar
- 11.Costa EM, Mendonca BB. Clinical management of transsexual subjects. Arq Bras Endocrinol Metabol. 2014;58(2):188–96.PubMedGoogle Scholar
- 12.Israel GE, Tarver DE. Transgender care: recommended guidelines, practical information, and personal accounts. Philadelphia: Temple University Press; 1997. xviii, 282 p.Google Scholar
- 13.Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017;5(4):301–11.PubMedGoogle Scholar
- 14.Meriggiola MC, Berra M. Safety of hormonal treatment in transgenders. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):565–9.PubMedGoogle Scholar
- 15.Spack NP. Management of transgenderism. JAMA. 2013;309(5):478–84.PubMedGoogle Scholar
- 16.Meriggiola MC, et al. Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline: commentary from a European perspective. Eur J Endocrinol. 2010;162(5):831–3.PubMedGoogle Scholar
- 17.Murad MH, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf). 2010;72(2):214–31.Google Scholar
- 18.Unger CA. Care of the transgender patient: the role of the gynecologist. Am J Obstet Gynecol. 2014;210(1):16–26.PubMedGoogle Scholar
- 19.Seal LJ, et al. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab. 2012;97(12):4422–8.PubMedGoogle Scholar
- 20.Wierckx K, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9(10):2641–51.PubMedGoogle Scholar
- 21.Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012;32(1):54–66.PubMedGoogle Scholar
- 22.Godano A, et al. SIAMS-ONIG consensus on hormonal treatment in gender identity disorders. J Endocrinol Invest. 2009;32(10):857–64.PubMedGoogle Scholar
- 23.Meriggiola MC, Berra M. Long-term cross-sex hormone treatment is safe in transsexual subjects. Asian J Androl. 2012;14(6):813–4.PubMedGoogle Scholar
- 24.Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19–25.PubMedGoogle Scholar
- 25.Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav. 1989;18(1):49–57.PubMedGoogle Scholar
- 26.Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations. J Clin Endocrinol Metab. 2014;99(12):4379–89.PubMedGoogle Scholar
- 27.Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(Suppl 2):31–6.PubMedGoogle Scholar
- 28.Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59(4):409–18.Google Scholar
- 29.Tangpricha V, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9(1):12–21.PubMedGoogle Scholar
- 30.Meriggiola MC, Gava G. Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Clin Endocrinol (Oxf). 2015;83(5):597–606.Google Scholar
- 31.Meriggiola MC, Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83(5):607–15.Google Scholar
- 32.Wylie K, et al. Serving transgender people: clinical care considerations and service delivery models in transgender health. Lancet. 2016;388(10042):401–11.PubMedGoogle Scholar
- 33.Feldman J, et al. Priorities for transgender medical and healthcare research. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):180–7.PubMedPubMedCentralGoogle Scholar
- 34.Dittrich R, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2005;113(10):586–92.PubMedGoogle Scholar
- 35.Gava G, et al. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Clin Endocrinol (Oxf). 2016;85(2):239–46.Google Scholar
- 36.Wilczynski C, Emanuele MA. Treating a transgender patient: overview of the guidelines. Postgrad Med. 2014;126(7):121–8.PubMedGoogle Scholar
- 37.Bourguignon JP, et al. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin). Eur J Pediatr. 1987;146(6):555–60.PubMedGoogle Scholar
- 38.Rappaport R, Fontoura M, Brauner R. Treatment of central precocious puberty with an LHRH agonist (Buserelin): effect on growth and bone maturation after three years of treatment. Horm Res. 1987;28(2–4):149–54.PubMedGoogle Scholar
- 39.Kjeld JM, et al. Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men. Clin Endocrinol (Oxf). 1979;11(5):497–504.Google Scholar
- 40.Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63(5):463–92.PubMedGoogle Scholar
- 41.Toorians AW, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88(12):5723–9.PubMedGoogle Scholar
- 42.Vita R, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study. Maturitas. 2018;107:92–6.PubMedGoogle Scholar
- 43.Wierckx K, Gooren L, T’Sjoen G. Clinical review: breast development in trans women receiving cross-sex hormones. J Sex Med. 2014;11(5):1240–7.PubMedGoogle Scholar
- 44.Orentreich N, Durr NP. Proceedings: mammogenesis in transsexuals. J Invest Dermatol. 1974;63(1):142–6.PubMedGoogle Scholar
- 45.Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88(8):3467–73.PubMedGoogle Scholar
- 46.Gil M, et al. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol. 2011;72(6):965–8.PubMedPubMedCentralGoogle Scholar
- 47.Ter Wengel PV, et al. Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia. 2016;48(10):1130–7.PubMedGoogle Scholar
- 48.Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med. 2007;357(23):2411–2.PubMedGoogle Scholar
- 49.Levy J, et al. Interaction of spironolactone with oestradiol receptors in cytosol. J Endocrinol. 1980;84(3):371–9.PubMedGoogle Scholar
- 50.Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015;125(3):605–10.PubMedPubMedCentralGoogle Scholar
- 51.Mosenkis A, Townsend RR. Gynecomastia and antihypertensive therapy. J Clin Hypertens (Greenwich). 2004;6(8):469–70.Google Scholar
- 52.Kreukels BPC, Steensma TD, de Vries ALC. Gender dysphoria and disorders of sex development: progress in care and knowledge. In: Focus on sexuality research. New York; Heidelberg: Springer; 2014. xxxii, 357 p.Google Scholar
- 53.Moretti C, et al. Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: a double-blind randomized controlled trial. Moretti C1, Guccione L1, Di Giacinto P1, Simonelli I2, Exacoustos C3, Toscano V4, Motta C4, De Leo V5, Petraglia F5, Lenzi A6. J Clin Endocrinol Metab. 2018;103(3):824–38.Google Scholar
- 54.Muderris II, et al. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endocrinol. 2002;16(1):63–6.PubMedGoogle Scholar
- 55.Calaf J, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab. 2007;92(9):3446–52.PubMedGoogle Scholar
- 56.Castelo-Branco C, et al. Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertil Steril. 2009;91(4):1183–8.PubMedGoogle Scholar
- 57.Dikensoy E, et al. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet. 2009;279(3):321–7.PubMedGoogle Scholar
- 58.Irwig MS. Safety concerns regarding 5alpha reductase inhibitors for the treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):248–53.PubMedGoogle Scholar
- 59.Available from: http://transhealth.ucsf.edu/trans?page=guidelines-feminizing-therapy (2/15/2018).
- 60.Ettner R. Care of the elderly transgender patient. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):580–4.PubMedGoogle Scholar
- 61.Mepham N, et al. People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge. J Sex Med. 2014;11(12):2995–3001.PubMedGoogle Scholar
- 62.de Blok CJM, et al. Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. J Clin Endocrinol Metab. 2018;103(2):532–8.PubMedGoogle Scholar
- 63.Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–31.PubMedPubMedCentralGoogle Scholar
- 64.Asscheman H, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014;46(7):791–5.PubMedGoogle Scholar
- 65.van Kesteren PJ, et al. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47(3):337–42.Google Scholar
- 66.Costa R, Colizzi M. The effect of cross-sex hormonal treatment on gender dysphoria individuals’ mental health: a systematic review. Neuropsychiatr Dis Treat. 2016;12:1953–66.PubMedPubMedCentralGoogle Scholar
- 67.Rossouw JE, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women’s health initiative trials of hormone therapy. Arch Intern Med. 2008;168(20):2245–53.PubMedPubMedCentralGoogle Scholar
- 68.Miller VT, et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. The writing group for the PEPI trial. JAMA. 1995;273(3):199–208. https://doi.org/10.1001/jama.1995.03520270033028.Google Scholar
- 69.Ott J, et al. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med. 2011;8(8):2361–9.PubMedGoogle Scholar
- 70.Singh-Ospina N, et al. Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3904–13.PubMedGoogle Scholar
- 71.Elbers JM, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 2003;58(5):562–71.Google Scholar
- 72.Wierckx K, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999–2011.PubMedGoogle Scholar
- 73.Kovacs K, et al. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med. 1994;118(5):562–5.PubMedGoogle Scholar
- 74.Serri O, et al. Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab. 1996;81(9):3177–9.PubMedGoogle Scholar
- 75.Cunha FS, et al. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia. 2015;47(6):680–4.PubMedGoogle Scholar
- 76.Freda PU, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894–904.PubMedPubMedCentralGoogle Scholar
- 77.Giltay EJ, et al. Sex steroids, insulin, and arterial stiffness in women and men. Hypertension. 1999;34(4 Pt 1):590–7.PubMedGoogle Scholar
- 78.Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin North Am. 2011;40(2):419–32, ix.PubMedGoogle Scholar
- 79.Wierckx K, et al. Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med. 2014;11(1):107–18.PubMedGoogle Scholar
- 80.Steinle K. Hormonal management of the female-to-male transgender patient. J Midwifery Womens Health. 2011;56(3):293–302.PubMedGoogle Scholar
- 81.Meyer WJ 3rd, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Send to Arch Sex Behav. 1986;15(2):121–38.PubMedGoogle Scholar
- 82.Tack LJ, et al. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. Biol Sex Differ. 2016;7:14.PubMedPubMedCentralGoogle Scholar
- 83.Darney PD. The androgenicity of progestins. Am J Med. 1995;98(1A):104S–10S.PubMedGoogle Scholar
- 84.Leder BZ, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004;89(3):1174–80.PubMedGoogle Scholar
- 85.T’Sjoen GG, et al. Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab. 2005;90(10):5717–22.PubMedGoogle Scholar
- 86.Ott J, et al. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93(4):1267–72.PubMedGoogle Scholar
- 87.Buckler HM, et al. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf). 1998;49(2):173–8.Google Scholar
- 88.Gorton RN, Buth J, Spade D. Medical therapy and health maintenance for transgender men: a guide for health care providers. San Francisco, CA: Lyon-Martin Women’s Health Services; 2005. http://www.lyon-martin.org
- 89.Coviello AD, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914–9.PubMedGoogle Scholar
- 90.Dickerman RD, et al. Androgen-induced erythrocytosis: is it erythropoietin? Am J Hematol. 1999;61(2):154–5.PubMedGoogle Scholar
- 91.Dobs AS, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78.PubMedGoogle Scholar
- 92.Mueller A, et al. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab. 2007;92(9):3470–5.PubMedGoogle Scholar
- 93.Gooren LJ. Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes. 2014;21(3):233–8.PubMedGoogle Scholar
- 94.Asscheman H, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164(4):635–42.PubMedGoogle Scholar
- 95.Gooren LJ, Giltay EJ. Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects. Andrologia. 2014;46(5):570–5.PubMedGoogle Scholar
- 96.Costantino A, et al. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther. 2013;39(4):321–35.PubMedGoogle Scholar
- 97.Mueller A, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med. 2010;7(9):3190–8.PubMedGoogle Scholar
- 98.Dhejne C, et al. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PLoS ONE. 2011;6(2):e16885.PubMedPubMedCentralGoogle Scholar
- 99.Wierckx K, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169(4):471–8.PubMedGoogle Scholar
- 100.Deutsch MB, Feldman JL. Updated recommendations from the world professional association for transgender health standards of care. Am Fam Physician. 2013;87(2):89–93.PubMedGoogle Scholar
- 101.Polderman KH, et al. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab. 1994;79(1):265–71.PubMedGoogle Scholar
- 102.Berra M, et al. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl. 2006;8(6):725–9.PubMedGoogle Scholar
- 103.Colizzi M, et al. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study. J Psychosom Res. 2015;78(4):399–406.PubMedGoogle Scholar
- 104.Pelusi C, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014;11(12):3002–11.PubMedGoogle Scholar
- 105.Dunaif A, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–74.PubMedGoogle Scholar
- 106.Fernandez JD, Tannock LR. Metabolic effects of hormone therapy in transgender patients. Endocr Pract. 2016;22(4):383–8.PubMedGoogle Scholar
- 107.Emmelot-Vonk MH, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52.PubMedGoogle Scholar
- 108.Doublier S, et al. Testosterone and 17beta-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int. 2011;79(4):404–13.PubMedGoogle Scholar
- 109.Soljancic A, et al. Protective role of testosterone in ischemia-reperfusion-induced acute kidney injury. Am J Physiol Regul Integr Comp Physiol. 2013;304(11):R951–8.PubMedPubMedCentralGoogle Scholar
- 110.Ikeda K, et al. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Hum Reprod. 2013;28(2):453–61.PubMedGoogle Scholar
- 111.Galazis N, et al. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration. Fertil Steril. 2012;98(6):1590–601 e1.Google Scholar
- 112.Grynberg M, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online. 2010;20(4):553–8.PubMedGoogle Scholar
- 113.Baba T, et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod. 2007;22(4):1011–6.PubMedGoogle Scholar
- 114.Pache TD, Fauser BC. Polycystic ovaries in female-to-male transsexuals. Clin Endocrinol (Oxf). 1993;39(6):702–3.Google Scholar
- 115.Coleman E, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13(4):165–232.Google Scholar
- 116.Slagter MH, et al. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem. 2006;54(8):905–10.PubMedGoogle Scholar
- 117.Gooren LJ, et al. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013;10(12):3129–34.PubMedGoogle Scholar
- 118.Gooren L, et al. Five new cases of breast cancer in transsexual persons. Andrologia. 2015;47(10):1202–5.PubMedGoogle Scholar
- 119.Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer. 2011;11(6):417–9.PubMedGoogle Scholar
- 120.Burcombe RJ, et al. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast. 2003;12(4):290–3.PubMedGoogle Scholar
- 121.Nikolic DV, et al. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol. 2012;10:280.PubMedPubMedCentralGoogle Scholar
- 122.Mahan RJ, et al. Drug therapy for gender transitions and health screenings in transgender older adults. J Am Geriatr Soc. 2016;64(12):2554–9.PubMedGoogle Scholar
- 123.Primary care protocol for transgender patient care. Center of Excellence for Transgender Health, University of California, San Francisco, Department of Family and Community Medicine. [online] available at http://transhealth.ucsf.edu/protocols (2011). Accessed 5 Feb 2018.
- 124.Baldassarre M, et al. Effects of long-term high dose testosterone administration on vaginal epithelium structure and estrogen receptor-alpha and -beta expression of young women. Int J Impot Res. 2013;25(5):172–7.PubMedGoogle Scholar
- 125.Roberts TK, et al. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med. 2014;127(2):159–62.PubMedGoogle Scholar
- 126.Callewaert F, et al. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol. 2010;207(2):127–34.PubMedGoogle Scholar
- 127.Lips P, et al. The effect of androgen treatment on bone metabolism in female-to-male transsexuals. J Bone Miner Res. 1996;11(11):1769–73.PubMedGoogle Scholar
- 128.Van Caenegem E, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab. 2012;97(7):2503–11.PubMedGoogle Scholar
- 129.Ruetsche AG, et al. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporos Int. 2005;16(7):791–8.PubMedGoogle Scholar
- 130.Turner A, et al. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin Endocrinol (Oxf). 2004;61(5):560–6.Google Scholar
- 131.Van Caenegem E, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013;54(1):92–7.PubMedGoogle Scholar
- 132.Van Caenegem E, et al. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos Int. 2015;26(1):35–47.PubMedGoogle Scholar
- 133.Fischer EM, et al. Severe osteoporosis with multiple vertebral fractures after gender reassignment therapy—is it male or female osteoporosis? Gynecol Endocrinol. 2011;27(5):341–4.PubMedGoogle Scholar
- 134.Amin S, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med. 2000;133(12):951–63.PubMedGoogle Scholar
- 135.Khosla S, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86(8):3555–61.PubMedGoogle Scholar
- 136.Argalious MY, et al. Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing noncardiac surgery. Anesthesiology. 2017;127(3):457–65.PubMedGoogle Scholar